Results for: BCDA

BioCardia Inc. (BCDA) shares experienced a significant decline of 12% on Friday after the company announced an upsized public offering. The offering involves the sale of 2.4 million shares of common stock or pre-funded warrants, accompanied by warrants to purchase an additional 2.4 million shares. The proceeds from the offering will be used to fund working capital, general corporate purposes, and advance BioCardia’s biotherapeutic initiatives.

BioCardia Inc (BCDA) shares skyrocketed on Thursday after receiving FDA clearance for its Morph DNA Steerable Introducer product family, designed to facilitate medical instrument insertion during cardiovascular procedures. The company expects this new product line to enhance outcomes for a variety of interventional procedures.